Janux ends development of Tumor Activated T Cell Engager asset
Janux Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $14.41
-5.6% in 3d after detection
Post-detection moves
1h
—
1d
-4.8%
3d
-5.6%
7d
-4.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS